These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36922858)

  • 1. Decrease in naturally occurring antibodies against epitopes of Alzheimer's disease (AD) risk gene products is associated with cognitive decline in AD.
    Gu D; Wang L; Zhang N; Wang H; Yu X
    J Neuroinflammation; 2023 Mar; 20(1):74. PubMed ID: 36922858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease.
    Liu YH; Wang J; Li QX; Fowler CJ; Zeng F; Deng J; Xu ZQ; Zhou HD; Doecke JD; Villemagne VL; Lim YY; Masters CL; Wang YJ
    Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33523832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Naturally Occurring Antibodies to P2RY2 Are Decreased in Alzheimer's Disease.
    Jian JM; Fan DY; Cheng Y; Shen YY; Chen DW; Li HY; Chen Y; Zhang Y; Zeng GH; Tan CR; Liu YH; Wang YJ
    J Alzheimers Dis; 2022; 87(2):711-719. PubMed ID: 35342089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-β Load and Cognitive Impairment in Alzheimer's Disease.
    Wang YR; Wang MT; Zeng XQ; Liu YH; Wang YJ
    J Alzheimers Dis; 2022; 90(4):1493-1500. PubMed ID: 36278353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.
    Li TR; Yao YX; Jiang XY; Dong QY; Yu XF; Wang T; Cai YN; Han Y
    Alzheimers Res Ther; 2022 May; 14(1):66. PubMed ID: 35550625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.
    Jian JM; Fan DY; Tian DY; Cheng Y; Sun PY; Tan CR; Zeng GH; He CY; Wang YR; Zhu J; Yao XQ; Wang YJ; Liu YH
    Neurosci Bull; 2022 Sep; 38(9):1025-1040. PubMed ID: 35570231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
    Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
    J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
    Sheng C; Yang K; He B; Du W; Cai Y; Han Y
    Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.